Navigation Links
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Date:8/27/2008

a and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite decreased (including anorexia) (each 36%), pyrexia (34%), vomiting (33%), anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), arthralgia (17%), neutropenia and dizziness (excluding vertigo) (each 17%), pain in limb and abdominal pain (each 15%), bone pain (14%), back pain and hypotension (each 13%), herpes zoster, nasopharyngitis, upper respiratory tract infection, myalgia and pneumonia (each 12%), muscle cramps (11%), and dehydration and anxiety (each 10%). Twenty percent (20%) of patients experienced at least 1 episode of greater than or equal to Grade 4 toxicity, most commonly thrombocytopenia (5%) and neutropenia (3%). A total of 50% of patients experienced serious adverse events (SAEs) during the studies. The most commonly reported SAEs included pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

About Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy. Between 2001 - 2005, the median age of diagnosis was 70 years. In 2007, there were 110,000 patients living with multiple myeloma across the United States, Europe and Japan. It is estimated that this number will increase by 5.6 % annually over the next few years due to new therapies extending the lives of multiple myeloma patients.

About VELCADE

VELCADE is being co-developed by Millennium: The Takeda Oncology Company and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercia
'/>"/>

SOURCE Millennium
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... with certain of its shareholders, has closed the transaction ... ("Medna").  Medna has acquired (the "Escrow Transfer") a total ...
(Date:4/24/2015)... -- Elekta has CE marked the latest version (v5.10) of ... European clinics to deliver a sophisticated radiation therapy planning ... planning, IMRT, VMAT and stereotactic planning – all in ... ® v5.10 provides significant planning and ... 3D planning as well as the addition of MRI ...
(Date:4/23/2015)... CHICAGO, Ill. , April 24, 2015  AbbVie ... Food and Drug Administration (FDA) has accepted its New ... company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, ... for the treatment of adults with chronic genotype 4 ... regimen is the first all-oral, interferon-free therapy being evaluated ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Elekta CE marks for Monaco v5.10 treatment planning system 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... Knopp Neurosciences Inc. ("Knopp"),announced that the U.S. ... Development has granted orphan drug designation to ... (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... studies to evaluate the safety,tolerability and pharmacokinetics ...
... on stringent endpoint of clinical ... PHILADELPHIA, Oct. 15 An analysis of data to,be ... Scientific Meeting found that Asacol, dosed at 2.4 g/day, ... active,ulcerative colitis (UC). The analysis was based on data ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 3New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 4
(Date:4/25/2015)... In the United States alone, an ... treatment for an illicit drug or alcohol ... Mental Health Services Administration’s Survey on Drug Use and ... are harrowing stories of men and women whose lives ... David H. Kerr , founder and retired president of ...
(Date:4/25/2015)... New York, NY (PRWEB) April 25, 2015 ... systems, technology and data for the enterprise relying on their ... and running smoothly. But according to an article ... CIOs can many times actually be doing a disservice to ... the i’s are dotted and t’s are crossed when it ...
(Date:4/25/2015)... Gardant Management Solutions will lead ... operations, and sales and marketing at the LeadingAge ... be held from April 29 through May 1 ... largest eldercare association in Illinois. The statewide association ... adults, including senior housing, assisted living and supportive ...
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse and violence. ... the Miami Dolphins and Richie Incognito, or off the field and ... abuse case. In a recent episode of SCI TV , ... locker room culture on teams. He examines what worked for the ... improve the locker room as a work place. , Steele ...
(Date:4/24/2015)... 24, 2015 Bird B Gone, the leader ... now offers a complete line of bird control solutions to ... , New Flu Strains Threaten Pacific, Central and Mississippi Farms ... , a number of highly pathogenic avian flus in ... is often spread when wild birds enter poultry farms. The ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4
... back, the 2008 Compensation Data results show benefits have seen little change ... ... October 29, 2008 -- General Motors has made headlines with plans to ... Retirees are also slated to loose health insurance coverage when they reach ...
... commercial with Jenny,Craig celebrity client, Valerie Bertinelli, ... pleased to,announce the three grand finalists of their ... Elaina Faustino and,Sara Hennessy are the three women ... TV commercial with Jenny Craig star client, Valerie ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (WorldHeart or ... filing of articles of amendment with Industry,Canada under the ... Capital Market on a post-consolidation basis on October 28,2008. ... split at a Special Meeting of Shareholders held on ...
... Quarter Net Sales of $3.9 Million; 29% Increase ... - Second Fiscal Quarter U.S. Sales of $2.2 Million; 83% Increase ... Year-Over-Year -, - Multicenter Clinical Study Launched to Expand Reimbursement, Support ... Marketing - - Conference Call to be Held ...
... Oct. 29 Heralding the newest innovation,in home skin ... of light therapy, has announced the retail launch of ... Quasars are widely,acclaimed as the first professional devices made ... the Baby Quasar delivers exceptional,skin care results and can ...
... cloud symptoms, study says , , WEDNESDAY, Oct. 29 (HealthDay News) ... in people if they have other medical conditions, a new ... high cholesterol appeared to mask early MS symptoms and lead ... in the Oct. 29 online issue of Neurology . ...
Cached Medicine News:Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 2Health News:Cuts at General Motors Bring Benefit Trends to the Forefront 3Health News:Jenny Craig Announces Finalists for the 2008 Ideal Size Contest 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 2Health News:WorldHeart Announces Effectiveness of Reverse Stock Split 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 2Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 3Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 4Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 5Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 6Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 7Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 8Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 9Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 10Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 11Health News:Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009 12Health News:Baby Quasar Lights Up Dillard's for the Retail Holiday Season 2Health News:Other Health Problems Can Delay MS Diagnosis 2
... Wristbands and Tags print in mere ... transfer printers. Direct thermal printers use ... coating under the bands protective surface. ... transfer highly durable ink from a ...
... in settings where a more secure band is ... easy to apply but difficult to remove wristband ... to suit the child. An additional label is ... wristband to ensure proper identification of the child. ...
IDENTI-MATCH II is a combination of the IDENTI-MATCH Blood Recipient Identification System and an admitting band. It has been designed for those facilities using label-based patient ID systems....
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
Medicine Products: